Evidence map›Paper›PMID 38284724›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2024

Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues.

Salvatore Raia, Sabrina Chiloiro, Antonella Giampietro, Maria Grazia Maratta, Fabia Attili, Maria Gabriella Brizi, Vittoria Rufini, Laura De Marinis, Alfredo Pontecorvi, Guido Rindi and 2 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Salvatore RaiaInternal Medicine, Endocrinology and Diabetes Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Sabrina ChiloiroInternal Medicine, Endocrinology and Diabetes Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Antonella GiampietroInternal Medicine, Endocrinology and Diabetes Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.ORCID 0000-0001-5756-2045
Maria Grazia MarattaENETS Center of Excellence, Rome, Italy.
Fabia AttiliENETS Center of Excellence, Rome, Italy.
Maria Gabriella BriziENETS Center of Excellence, Rome, Italy.
Vittoria RufiniENETS Center of Excellence, Rome, Italy.
Laura De MarinisInternal Medicine, Endocrinology and Diabetes Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Alfredo PontecorviInternal Medicine, Endocrinology and Diabetes Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Guido RindiENETS Center of Excellence, Rome, Italy.
Giovanni SchinzariDipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Antonio BianchiInternal Medicine, Endocrinology and Diabetes Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic metastases from medullary thyroid carcinoma (MTC) are exceptional. Imaging and treatment based on somatostatin receptors may play a role, though the evidence is unconvincing. CASE PRESENTATION: We have, herein, documented a unique case of metastatic MTC, where pancreatic metastasis was identified by 68Ga-PET/CT, with the disease showing very slow progression during treatment with lanreotide autogel. A 51-year-old woman underwent total thyroidectomy for goiter in 2000, with a postoperative diagnosis of MTC. Due to persistent disease, somatostatin analogues (SSA) treatment commenced in 2005, following a positive acute octreotide test. In 2012, a pathology-confirmed pancreatic metastasis was diagnosed via 68Gallium-positron emission tomography (68Ga-PET/CT). The disease progressed very slowly over 17 years of SSA treatment.

conclusionThis uncommon case of pancreatic metastasis from MTC indicates that nuclear medicine techniques might offer valuable additional information. Extended treatment with lanreotide autogel appears to correlate with very slow disease progression in selected patients.

Indexed as

Carcinoma, NeuroendocrinePancreatic NeoplasmsPeptides, CyclicSomatostatinThyroid NeoplasmsDisease ProgressionFemaleFollow-Up StudiesHumansMiddle AgedPositron Emission Tomography Computed TomographyTime FactorsTreatment OutcomelanreotidePeptides, CyclicSomatostatinclinical diagnosisMedullary thyroid carcinoma (MTC)multinodular goiter (MNG)nuclear medicine techniques.pancreatic metastasissomatostatin receptor ligands

Identifiers

PMID38284724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.